Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
Status:
Completed
Trial end date:
2020-01-24
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ruxolitinib phosphate works in treating patients with
chronic neutrophilic leukemia (CNL) or atypical chronic myeloid leukemia (aCML). Ruxolitinib
phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for
cells to reproduce. This trial also studies the genetic makeup of patients. Certain genes in
cancer cells may determine how the cancer grows or spreads and how it may respond to
different drugs. Studying how the genes associated with CNL and aCML respond to the study
drug may help doctors learn more about CNL and aCML and improve the treatment for these
diseases.